(PO30-08-22) Postdiagnosis Multivitamin and Individual Vitamin Supplement Use and Mortality Among Patients With Colorectal Cancer in the NIH–AARP Diet and Health Study

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

Zeinab Farhat, PhD, MPH
– Postdoctoral Fellow, National Cancer Institute, Bethesda, Maryland, United States

Co-Author(s)

LL

Linda Liao
– National Cancer Institute
MI

Maki Inoue-Choi
– National Cancer Institute
RP

Ruth Pfeiffer
– National Cancer Institute
SW

Stephanie J. Weinstein, PhD
– Staff Scientist, US National Cancer Institute, NIH, Bethesda, Maryland, United States
RS

Rashmi Sinha
– NIH/NCI
YP

Yikyung Park
– National Cancer Institute
EL

Erikka Loftfield
– NIH/NCI

Disclosure(s):

Zeinab Farhat, PhD, MPH: No relevant financial relationship(s) with ineligible companies to disclose.

Objectives: We aimed to evaluate the association of postdiagnostic multivitamin and individual vitamin supplement use with total and cancer-specific mortality among colorectal cancer (CRC) survivors.

Methods: In the National Institutes of Health (NIH)–AARP Diet and Health Study, we estimated the associations between vitamin use and total mortality and cancer-specific mortality risk among 2,136 CRC survivors. Use of multivitamin and individual vitamins (vitamin A, vitamin C, vitamin E, beta-carotene, and calcium) were assessed by a food-frequency questionnaire at baseline in 1995-1996 and follow-up questionnaire in 2004-2005. Participants reported frequency of use as never, < 1 time per week, 1-3 times per week, 4-6 times per week, or every day and categories were assigned a corresponding value (never = 0, < 1 time per week = 0.5, 1-3 times per week = 2, 4-6 times per week= 5, and every day = 7). Based on the sum of these values, participants were assigned to one of the following groups: never use (0 times/week), casual use ( >0 to 6 times/week), consistent use (7 times/week), or heavy use ( >7 times/week). Vital status was ascertained annually by linkage to the Social Security Administration Death Master File and the National Death Index Plus through December 31, 2019. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models with age as the underlying time metric and adjusting for potential confounders.

Results: Postdiagnosis multivitamin use was not associated with all-cause mortality or CRC-specific mortality, but consistent, as compared with never, postdiagnosis vitamin A use was associated with a 12% lower risk of total mortality (HR: 0.88, 95% CI: 0.78-1.00). Consistent, as compared with never, postdiagnosis vitamin C and calcium use were also associated with lower risk of total mortality (HR: 0.86, 95% CI: 0.75-0.99 and HR: 0.84 95% CI: 0.73-0.97, respectively). Use of vitamin E or beta-carotene supplements were not associated with total mortality or CRC-specific mortality.

Conclusions: In the NIH-AARP cohort, consistent use of vitamin A, vitamin C, and calcium but not multivitamins was associated with lower total mortality and CRC-specific mortality among CRC cancer survivors.

Funding Sources: This work was supported by the NCI Intramural Research Program.